Pharma Resources and Bionical Emas Announce Exclusive Global Clinical Trial Supply Partnership
Strategic agreement secures access to essential oncology injectables for clinical trials as European shortages intensify
HAMELN, GERMANY – 17 JUNE 2025: Pharma Resources GmbH announces an exclusive global clinical trial supply agreement with Bionical Emas, a global provider of Clinical Trial Services. This strategic partnership marks Pharma Resources’ entry into the clinical trial supply market and grants Bionical Emas exclusive rights to distribute its EU-marketed oncology injectables, including Fluorouracil, which is currently in critical shortage across Europe.
The agreement comes at a crucial time, with 5-Fluorouracil shortages disrupting cancer treatments and clinical trials across Europe. Pharma Resources agile supply chain will cut delivery times from months to weeks, ensuring faster, more reliable access to essential medications. By combining advanced demand forecasting with proactive inventory strategies, Bionical Emas and Pharma Resources are addressing long-standing supply chain challenges –accelerating trial timelines and improving flexibility for investigational sites.
Juliana Dodillet, Managing Director at Pharma Resources, commented: “We are thrilled to partner with Bionical Emas, whose proven global reach and deep expertise in clinical trial supply make them the ideal partner to support the launch of our first clinical trial supply program and maximize the reach of our oncology injectable portfolio. This collaboration ensures our products can support the development of new therapies and improve patient outcomes, particularly at a time when Fluorouracil shortages are significantly impacting access across Europe.”
Tom White, Senior Vice-President, Strategic Alliances at Bionical Emas, commented: "This strategic agreement underscores our unwavering commitment to delivering innovative, patient-focused solutions to the clinical trial community. With our global infrastructure and established expertise in the industry, Pharma Resources has proven to be an exceptionally dedicated and agile partner, and together we're ensuring uninterrupted access to vital oncology treatments for patients worldwide."
All clinical trial enquiries should be sent to: pharmaresources@bionicalemas.com
|
Folinic Acid PhaRes 10 mg/ml PZN 12476618 (Calcium Folinate 100 ml/1000 mg)
Folinic Acid PhaRes 10 mg/ml PZN 12476601 (Calcium Folinate 50 ml/500 mg)
We are currently offering the above-mentioned products at a special price.
If you are interested, we would be happy to send you a quote. Delivery is immediate from stock. If you would like to place an order, please contact:
Mr. Juri Paul Deppemeier
Email: jdeppenmeier@pha-res.com
Phone: +49 5151 6099629
We are available to answer any questions you may have.
We offer a wide range of oncological products and accompanying therapies for the ambulant and stationary use.
Our core competence is to offer a stable supply chain with high-quality oncological products. The product portfolio is based on up to date dossiers and marketing authorisations. Working on a high-quality level is to be given for our manufacturers which will be audited in regular intervals by us. Therefore, we can offer you a product supply chain within Germany, in Europe and internationally on the highest standard.
Quality and Security are our top priorities!
To avoid application mistake, we have developed a packaging system with unique product signs and strength signs. In the area of oncology several drugs are often given in combination. For the expert staff it is important to find the right product with the correct strength and volume on the first view. With this individual identification labels we like to support the expert oncology staff within its daily work.
We always try to work with our customers hand in hand. Convince yourselves and contact us.
